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Ancient and modern anticonvulsants act
synergistically in a KCNQ potassium channel
binding pocket
Rían W. Manville1 & Geoffrey W. Abbott1
Epilepsy has been treated for centuries with herbal remedies, including leaves of the African
shrub Mallotus oppositifolius, yet the underlying molecular mechanisms have remained
unclear. Voltage-gated potassium channel isoforms KCNQ2–5, predominantly KCNQ2/3
heteromers, underlie the neuronal M-current, which suppresses neuronal excitability, pro-
tecting against seizures. Here, in silico docking, mutagenesis and cellular electrophysiology
reveal that two components of M. oppositifolius leaf extract, mallotoxin (MTX) and isovaleric
acid (IVA), act synergistically to open neuronal KCNQs, including KCNQ2/3 channels.
Correspondingly, MTX and IVA combine to suppress pentylene tetrazole-induced tonic
seizures in mice, whereas individually they are ineffective. Co-administering MTX and IVA
with the modern, synthetic anticonvulsant retigabine creates a further synergy that voltage
independently locks KCNQ2/3 open. Leveraging this synergy, which harnesses ancient and
modern medicines to exploit differential KCNQ isoform preferences, presents an approach to
developing safe yet effective anticonvulsants.
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Epilepsy affects over 50 million people worldwide, withapproximately 50% being inadequately treated with cur-rently available anti-epileptic drugs1. In the developing
world, an estimated 80% of epilepsy patients use herbal remedies
for primary healthcare2,3. Extract taken from leaves of the shrub
Mallotus oppositifolius has been used traditionally in folk medi-
cine to treat disorders such as seizures in African countries4,5
including Ghana, where it is known as nyanyaforowa (pimpim),
and Nigeria, where it is referred to as okpo-biriba. Accordingly,
M. oppositifolius extract has been shown to delay the onset, fre-
quency, and duration of seizures in the acute chemoconvulsant
(pentylene tetrazole) mouse model5. Despite the clear therapeutic
effects of M. oppositifolius, the active anticonvulsant components
of this extract have remained unclear, and their molecular targets
unknown. Mallotoxin (MTX; a.k.a. rottlerin) is one suggested
anti-seizure component of M. oppositifolius. However, a plausible
molecular target for MTX that would quell seizures has not
previously been identiﬁed. In addition, some other plants heavily
used in folk medicine also contain MTX but are not traditionally
used to treat epilepsy. For example, Mallotus philippensis, a per-
ennial shrub distributed in outer Himalayan lowlands, is reported
to possess antiﬁlarial, antifertility, antibiotic, anti-inﬂammatory,
and a range of other properties but is not reportedly used to treat
seizures6. We therefore hypothesized that MTX either is not the
active anticonvulsant in M. oppositifolius or does not act alone.
Members of the KCNQ (Kv7) subfamily of voltage-gated
potassium (Kv) channels are essential for control of cellular
excitability and repolarization in a wide range of cell types. Kv
channels, including the KCNQs, are composed of tetramers of α
subunits each containing six transmembrane segments (S1–S6),
split into a voltage-sensing domain (S1–S4) and a pore module (S5
and S6) (Fig. 1a, b)7. KCNQ2–5 channels—predominantly
KCNQ2/3 heteromers—generate the M-current, a muscarinic-
inhibited Kv current that regulates neuronal excitability8,9. Muta-
tions in KCNQ2 and KCNQ3 subunits underlie various forms of
epilepsy, including early infantile epileptic encephalopathy, benign
familial neonatal seizures, and other miscellaneous early onset
encephalopathies10–12. Accordingly, retigabine (RTG) (also known
as ezogabine) is a ﬁrst-in-class anticonvulsant that works by acti-
vating KCNQ2/3 channels, negative-shifting their voltage depen-
dence to increase their open probability at subthreshold potentials
and prevent aberrant neuronal excitability13–18.
RTG was approved by the FDA in 2011 and was in clinical use
as an add-on therapy for the treatment of partial seizures in
adults with epilepsy until 2017, when it was withdrawn from the
market because of side effects including blue skin discoloration
and retinal pigment changes. More recently, the skin discolora-
tion has been found to be reversible after drug
discontinuation19,20. RTG activates all neuronally expressed
KCNQ isoforms (KCNQ2–5), with a preference for KCNQ3
(ref. 21), and in addition to epilepsy showed promise in treating
disorders including anxiety, neuropathic pain, neurodegenerative
disorders, cancer, inﬂammation, and ophthalmic diseases22–25.
New drugs are therefore needed that share mechanistic com-
monalties with RTG but lack the side effects, and ideally pos-
sessing improved efﬁcacy and/or potency, to reduce the required
dosage.
Here, we report that two components of M. oppositifolius leaf
extract, MTX and IVA, act synergistically in similar binding
pockets to activate KCNQ2/3 channels and reduce tonic seizure
incidence and related mortality in mice. We also demonstrate that
when co-administered, MTX, IVA, and RTG voltage-
independently lock KCNQ2/3 open at all voltages. We explain
the molecular mechanisms underlying these synergies, which
suggest a pathway for developing safer, more effective
anticonvulsants.
Results
Multiple M. oppositifolius leaf compounds activate KCNQ2/3.
Igwe et al.26 recently identiﬁed by mass spectrometry nine pri-
mary components of an ethanolic extract of the M. oppositifolius
leaf, in addition to MTX, which was previously identiﬁed in M.
oppositifolius bark and leaves27 (Fig. 1c). Using two-electrode
voltage-clamp electrophysiology, we screened all ten compounds
for their ability to activate heterologously expressed KCNQ2/3
channels in Xenopus laevis oocytes, with the exception of valeric
acid, which we had previously found to be inactive in this
respect28 (Fig. 1d). Compounds were screened at 100 µM, except
MTX and palmitic acid (30 µM). Four components—glutaconic
acid, isovaleric acid (IVA), MTX, and palmitic acid, negative-
shifted the voltage dependence of KCNQ2/3 activation, as
quantiﬁed using KCNQ2/3 tail currents at −30 mV immediately
following channel activation at voltages between −80 mV and
+40 mV (Fig. 1e, f). Three of these compounds (MTX excepted)
possessed strong negative electrostatic surface potential close to a
carbonyl oxygen, a property previously shown important for
KCNQ2/3 activation by RTG and related synthetic antic-
onvulsants29. One component (2-mercaptophenol) positive-
shifted KCNQ2/3 voltage dependence, an effect more likely to
be pro- rather than anticonvulsant; the other components had
little-to-no effect on KCNQ2/3 activation (Fig. 1c–f; Supple-
mentary Figures 1–6; Supplementary Tables 1–9).
MTX potently activates KCNQ2/3 channels. MTX, a poly-
phenol, was the most potent KCNQ2/3 activator in our initial
screen (Fig. 1d–f). This was in contrast to a prior report in which
MTX was previously found to activate KCNQ1 (a cardiac and
epithelial Kv channel) and KCNQ4, while KCNQ2, KCNQ5, and
heteromeric KCNQ2/3 channels were concluded to be insensi-
tive30. However, the screening in that study was performed using
a cell membrane potential of +40 mV, a voltage that often fails to
uncover effects of openers that operate by negative-shifting the
voltage dependence of activation. Indeed, we likewise found little
effect of MTX on KCNQ2/3 at +40 mV, but we observed a
prominent activating effect at −60 mV and consequent −17 mV
negative shift in the midpoint voltage dependence (V0.5) of
KCNQ2/3 activation (Fig. 1e, f; Fig. 2a; Supplementary Figure 3;
Supplementary Table 5). At −60 mV, 100 µM MTX increased
KCNQ2/3 current seven-fold; the activation EC50 was 11.5 ± 0.2
µM (standard error of the mean, SEM) (Fig. 2b). MTX activation
of KCNQ2/3 began immediately upon wash-in, plateaued at 5
min, washed out slowly, but was rapidly inhibited by KCNQ-
speciﬁc blocker XE991 (Fig. 2c). MTX speeded KCNQ2/3 acti-
vation and slowed deactivation, consistent with open state sta-
bilization and closed state destabilization (Fig. 2d; Supplementary
Tables 10 and 11). MTX exerted potent effects on KCNQ2/3-
dependent membrane hyperpolarization (Fig. 2e), illustrative of
how MTX can KCNQ2/3-dependently dampen cellular excit-
ability. The observed effects were KCNQ2/3-dependent: MTX
had no effect on water-injected control oocytes (Fig. 2f) nor on a
different-subfamily Kv channel, KCNA1 (Fig. 2g).
MTX preferentially activates KCNQ2 channels. With respect to
homomeric M-channels, KCNQ2 exhibited the highest MTX
sensitivity, with an EC50 of 6.4 µM at −60 mV. KCNQ3* (an
expression-optimized KCNQ3-A315T mutant that ensures robust
currents)31 was twofold less sensitive than KCNQ2 (EC50, 13.0
µM), while KCNQ4 and KCNQ5 had MTX EC50 values of 20.2
and 67.1 µM, respectively (Fig. 2h, i; Supplementary Figures 7–10;
Supplementary Tables 12–15). MTX activation of homomeric
KCNQs was again most effective at −60 mV (Fig. 2j). Despite
relatively lower sensitivity, MTX was an effective KCNQ5 opener
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Fig. 1 Multiple M. oppositifolius leaf extract compounds activate KCNQ2/3. a KCNQ1–KCNQ3 chimeric structure model. b KCNQ topology (two of four
subunits shown). VSD voltage-sensing domain. c Structure and electrostatic surface potential (blue, positive; green neutral; red, negative) of M.
oppositifolius leaf extract components. Open red circles highlight strongly negative electrostatic surface potential. d Averaged KCNQ2/3 current traces in
response to voltage protocol (upper inset) when bathed in the absence (Control) or presence of M. oppositifolius leaf extract components (n= 4–16).
Dashed line indicates zero current level in this and all following current traces. e, f Mean effects of leaf extract components (as in d; n= 4–16) on:
e KCNQ2/3 raw tail currents at −30mV after prepulses as indicated; f G/Gmax. Error bars indicate SEM. Red boxes indicate KCNQ2/3 activation; black box
indicates KCNQ2/3 inhibition
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at higher concentrations, increasing −60 mV current eight-fold at
100 µM, similar to the effect on KCNQ2 at 100 µM and more
than double the effect on KCNQ3* and KCNQ4 (Fig. 2k). Among
the neuronal KCNQs, MTX (30 µM) had the greatest effect on the
midpoint voltage of KCNQ2 activation (−24 mV), comparable to
reported effects of RTG on KCNQ2 (−24 mV for 10 µM RTG17),
followed by KCNQ2/3 and KCNQ4 (each −17 mV), KCNQ5
(−14 mV), and KCNQ3* (−9 mV) (Supplementary Tables 5
and 12–15). This order of potency is in contrast to that of
RTG, which is KCNQ3 > KCNQ2/3 > KCNQ2 > KCNQ4 >
KCNQ5 (refs.17,23).
MTX binds close to the channel pore to activate KCNQ2/3.
RTG, an established KCNQ2/3 channel activator, requires
KCNQ2-W236, which is located on transmembrane segment 5
(S5; Fig. 3a) or its equivalent on KCNQ3 (W265) for activation;
these residues are thought to be required for RTG binding32.
KCNQ2-L275 (or L314, its equivalent in KCNQ3), close to the
selectivity ﬁlter, also inﬂuences RTG activation of KCNQ2 and
may impinge on or form part of the binding site33, as illustrated
here using in silico docking to a model chimeric structure derived
from the Xenopus KCNQ1 cryo-EM structure with KCNQ3 RTG
binding residues and close neighbors added (Fig. 3b, upper).
In silico docking simulations predicted binding of MTX in the
region of KCNQ3-W265, but not L314 (Fig. 3b, lower), in a
location we recently discovered to harbor an evolutionarily
conserved neurotransmitter binding pocket in KCNQ2–5 (ref. 28).
However, previous studies clearly show that KCNQ1, which lacks
the W265 equivalent, is activated by MTX30. This, together with
our KCNQ3 docking prediction, suggested that MTX might ﬁt in
a binding pocket close enough to be inﬂuenced by W265, but not
absolutely require it for binding. Electrophysiological analysis of
KCNQ2 and KCNQ3 channel mutants support this hypothesis.
Thus, leucine substitution of either KCNQ2-W236 or KCNQ3-
W265, or both, in KCNQ2/3 channel complexes reduced as much
as tenfold the potency of MTX, quantiﬁed as the negative shift in
voltage dependence of activation induced, but a similar maximal
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Fig. 2 MTX preferentially activates KCNQ2. a Voltage dependence of KCNQ2/3 current fold-increase by MTX (30 µM), plotted from traces as in Fig. 1 (n
= 9). b Dose response of KCNQ2/3 channels at −60mV for MTX (calculated EC50= 11.5 µM; n= 4–9). c Exemplar −60mV KCNQ2/3 current (left)
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06339-2
4 NATURE COMMUNICATIONS |  (2018) 9:3845 | DOI: 10.1038/s41467-018-06339-2 | www.nature.com/naturecommunications
efﬁcacy was achieved in the mutant channels (Fig. 3c, d;
Supplementary Figures 11–13; Supplementary Tables 16–18).
Due to the bulky nature of MTX, we predicted that its binding
within a pocket close to S5 would inﬂuence pore conformation,
potentially altering relative ion permeabilities. To assess this, we
ﬁrst conducted pseudo-bi-ionic substitution experiments, which
showed that MTX increased relative permeability of KCNQ2/3 to
Na+ and Cs+, and decreased permeability to Rb+, compared to K
+ (Fig. 3e, f). Secondly, we assessed the ratio of Rb+ conductance
to K+ conductance, GRb/GK, an alternative method to probe the
pore conformation of K+ channels (see Methods). By this
method, KCNQ2/3 exhibited a baseline GRb/GK value of 0.75 ±
0.10; application of MTX reduced the GRb/GK value to 0.52 ± 0.06
(Fig. 3g). Thus, MTX binding alters KCNQ2/3 pore conformation
sufﬁciently to alter relative ion permeabilities, and also to sense
W236/W265.
In further support of this hypothesis we found that GABOB (γ-
amino-β-hydroxybutyric acid), a high-afﬁnity KCNQ2/3 partial
agonist that binds close to KCNQ3-W265 (ref. 28), only partially
diminishes the effects of MTX on KCNQ2/3 channels (Fig. 4a–d;
Supplementary Table 19). This is consistent with MTX binding in
a similar binding pocket to GABOB, but not directly competing
for exactly the same binding site, which would result in
proportionately greater inhibition of MTX effects, as we
previously observed for GABOB with GABA or retigabine28.
Interestingly, in our initial screen we found that 2-
mercaptophenol inhibits KCNQ2/3 at 100 µM (Fig. 1c–e), while
at lower doses it is a mild KCNQ2/3 activator (Supplementary
Figure 4, Supplementary Table 6). In silico docking predicted that
2-mercaptophenol binds close to KCNQ3-W265 (Fig. 4e).
Strikingly, mutation to leucine of KCNQ2-W236 and KCNQ3-
W265 rendered KCNQ2/3 insensitive to 100 µM 2-
mercaptophenol (Fig. 4f, g; Supplementary Table 20). At this
dose, 2-mercaptophenol did not alter the ability of MTX (30 µM)
to activate KCNQ2/3 channels (Fig. 4h–j; Supplementary
Table 21). We conclude that despite the capacity of 2-
mercaptophenol to inhibit KCNQ2/3 if administered alone, when
co-administered with MTX (as in leaf extract) it cannot compete
out MTX. This likely arises for two reasons: ﬁrst, the 2-
mercaptophenol-binding site appears to be closer to W265
(Fig. 4e–g) than that of MTX, which does not absolutely require
W265 (Fig. 3). Second, in contrast to GABOB, 2-mercaptophenol
b
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is a low-afﬁnity inhibitor, only beginning to inhibit at ~100 µM
and activating at lower concentrations (Supplementary Figure 4,
Supplementary Table 6).
M. oppositifolius component IVA potently activates KCNQ2. In
addition to MTX, previous gas chromatography-mass spectro-
metry (GCMS) analysis of M. oppositifolius extract identiﬁed nine
additional compounds26, three of which we found to activate
KCNQ2/3 channels in our initial screen (Fig. 1). One, IVA, is a
phytocompound found both in M. oppositifolius leaf extract and
in the extract of valerian root (from Valeriana ofﬁcinalis)
(Fig. 5a). Valerian root has been used in herbal medicine for more
than two millennia, in ancient Greece and Rome for disorders
including insomnia, and since the sixteenth century in northern
England and Scotland for convulsions34,35. As recently as 2002,
an estimated 1.1% of the United States adult population (~2
million people) had used valerian root extract in the past week36.
IVA shares a chemical feature of RTG important for KCNQ2/3
activation, i.e., strongly negative electrostatic surface potential
close to a carbonyl oxygen (Fig. 5a) and is predicted by SwissDock
to bind close to KCNQ3-W265 (Fig. 5b). In addition to KCNQ2/3
(Fig. 1), IVA potently and effectively activated homomeric
KCNQ2 at −60 mV (EC50, 0.34 µM) and, to a lesser extent,
KCNQ3* (EC50, 0.5 µM) and KCNQ4 (EC50, 16.2 µM), with no
effect on KCNQ5 (Fig. 5c, d; Supplementary Figures 14–17;
Supplementary Tables 22–25). Like MTX, IVA did not alter
currents generated by KCNA1 (Supplementary Figure 18; Sup-
plementary Table 26).
As we also observed for MTX, IVA activation was voltage-
dependent and had the greatest fold-effect on current at −60mV
(Fig. 5c, e), shifting the KCNQ2 and KCNQ2/3 activation V0.5 by
–9 and −11 mV, respectively (Supplementary Tables 4 and 22).
Unlike what we observed for MTX (Fig. 3c, d), KCNQ2-W236/
KCNQ3-W265 were essential for IVA activation of KCNQ2/3
(Fig. 5e). Thus, IVA did not increase KCNQ2/3-W236L/W265L
current at −60 mV at any concentration (Fig. 5f; Supplementary
Figure 19; Supplementary Tables 27 and 28). Further, the W236L/
W265L mutation prevented IVA from shifting the V0.5 of
KCNQ2/3 activation at all concentrations, in sharp contrast to
the much more subtle effect of the same double mutation on
KCNQ2/3 activation by MTX (Fig. 5g; Supplementary Table 29).
Supporting the premise that IVA effects require the S5
tryptophan, KCNQ1 (which lacks the W) was IVA-insensitive
(Fig. 5h, i), whereas KCNQ1 is activated by MTX30. Also in
support of a binding site for IVA close to W236/W265, the partial
agonist GABOB28 was highly effective at competing out effects of
IVA on KCNQ2/3 (Fig. 5j–l; Supplementary Table 30).
We also performed dose responses for the remaining KCNQ2/
3-active compounds in M. oppositifolius leaf extract, i.e.,
glutaconic acid, 2-mercaptophenol, and palmitic acid, and in
addition tested oleamide because at 100 µM it slightly increased
KCNQ2/3 currents at higher voltages (Fig. 1e). However, none of
these compounds achieved the maximal efﬁcacy we observed for
IVA or MTX; as mentioned earlier, 2-mercaptophenol was
inhibitory at higher doses (Fig. 5m; Supplementary Figures 1–8;
Supplementary Tables 2 and 4–8).
MTX and IVA synergistically activate KCNQ2/3 channels.
Because our data identiﬁed MTX and IVA as the most active M.
oppositifolius components with respect to KCNQ2/3 activation,
and also suggested different binding positions for MTX and IVA
(Figs. 3b and 5b), we next tested their effects in combination.
MTX (30 µM) and IVA (500 µM) in combination strongly acti-
vated KCNQ2/3 current, especially at −60 mV, and shifted the
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V0.5 of activation by −23mV (Fig. 6a–c; Supplementary
Table 31). MTX and IVA in combination speeded KCNQ2/3
activation and slowed its deactivation >twofold (Fig. 6d; Sup-
plementary Tables 32 and 33). Strikingly, the IVA+MTX com-
bination synergistically increased KCNQ2/3 current at −60mV
by 24-fold, compared to ~ﬁvefold for either component alone
(Fig. 6e). A cocktail of the ﬁve KCNQ2/3-active components of
M. oppositifolius leaf extract produced a similar KCNQ2/3 V0.5
activation shift to that of IVA+MTX, again suggesting these two
as the most active and synergistic components (Fig. 6f–i). Further,
in silico docking studies suggested that IVA and MTX could ﬁt
together in the W265-proximal binding pocket, providing a
possible mechanistic basis for their synergy (Fig. 6j).
MTX and IVA synergistically protect against seizures. The
cellular electrophysiology data therefore predicted that MTX and
IVA would in combination be necessary and sufﬁcient to confer
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anticonvulsant activity, if KCNQ2/3 activation was the molecular
basis for this therapeutic action of the leaf extract. In mouse
pentylene tetrazole (PTZ) chemoconvulsant assays, MTX (20 mg/
kg) halved the clonic seizure incidence whereas IVA (20 mg/kg)
had no effect. At 10 mg/kg neither compound reduced clonic
seizures alone, but halved seizure incidence in combination
(Fig. 6k). MTX and IVA were only effective at reducing tonic
seizure incidence when applied in combination (halving inci-
dence at 10+ 10 mg/kg; Fig. 6l). Most strikingly, MTX and IVA
only increased survival in the seizure assay when administered in
combination (tripling survival, compared to vehicle, at 10+ 10
mg/kg; Fig. 6m). Thus, MTX and IVA act synergistically to
reduce seizures and seizure-related mortality in mice, mirroring
their effects on KCNQ2/3 activation.
MTX and IVA combine with RTG to lock KCNQ2/3 open. Our
results indicate that MTX binds close to the channel pore and
senses the KCNQ2/3 S5 tryptophans, while IVA absolutely
requires them for binding, and that KCNQ2 is the most MTX-
and IVA-sensitive isoform (Figs. 2–6). Previous studies showed
that in contrast, KCNQ3 is the most RTG-sensitive isoform17,23.
These ﬁndings suggested that RTG might synergize with MTX
and/or IVA. Accordingly, while RTG (10 µM) negative-shifted
the KCNQ2/3 activation V0.5 by −13 mV, RTG (10 µM)+ IVA
(500 µM) increased the ΔV0.5 to −32 mV, and RTG (10 µM)+
MTX (30 µM) produced a ΔV0.5 of −57 mV. Most strikingly, the
combination of all three compounds at these concentrations
locked KCNQ2/3 open, such that its activation was voltage-
independent from −120 mV to +40 mV, an effect to our
knowledge not previously reported for KCNQ2/3 with any other
drugs (Fig. 7a–d; Supplementary Table 34).
Kv channel openers are generally more effective at negative
membrane potentials because the lower open probability provides
more capacity for augmentation before the maximum open
probability is reached (in contrast to positive voltages). However,
at extremely hyperpolarized membrane potentials, the capacity of
channel openers such as RTG to activate diminishes again
(creating a bell-shaped voltage dependence to activation). In the
case of KCNQ2/3 this may be because of an inability to open the
channel from more stable closed conformations. However,
addition of MTX or IVA, and in particular both, to RTG
overcame this, resulting in potent current augmentation even at
−120 mV. Thus, MTX+ IVA+ RTG increased KCNQ2/3 cur-
rent by 60–80-fold at −80 to −120 mV (Fig. 7e).
MTX and IVA have been tolerated as part of herbal medicine
for centuries27,34,35. RTG was in clinical use for 6 years before
being withdrawn because of adverse off-target effects, although
these are now known to subside following RTG
discontinuation19,20. Given the synergy between MTX, IVA,
and RTG, we tested whether combining the three at low
concentrations could achieve efﬁcacy at potentially tolerable
RTG doses. At 1 µM, RTG had negligible effects on KCNQ2/3
(Fig. 7f), as we also observed for 1 µM MTX (Fig. 2b) and 1 µM
IVA (Fig. 5f). In contrast, the combination of 1 µM concentra-
tions of RTG, MTX, and IVA was a highly effective KCNQ2/3
opener, shifting the V0.5 of activation by −18 mV; a further
negative shift in voltage dependence was observed with 1 µM
RTG, 10 µM MTX, and 10 µM IVA (Fig. 7f; Supplementary
Table 35). The synergy was especially apparent when comparing
the fold-change in current at −60 mV induced by low doses of
RTG, MTX, and IVA applied alone versus in combination
(Fig. 7g, h).
We next further tested whether the heteromeric composition of
KCNQ2/3 channels afforded greater sensitivity to the synergistic
effects of IVA+MTX+ RTG than for the homomers. Studies of
relative ion permeabilities for heteromeric versus homomeric
channels revealed greater increases in relative Na+ and Cs+
permeability (Fig. 8a–c, upper) compared to effects of MTX alone
(Fig. 3f), suggesting that the triple-drug combination exerted
greater effects than MTX alone on KCNQ2/3 pore conformation.
However, the triple-drug combination also induced similar Na+
and Cs+ permeability relative to K+ in homomeric KCNQ2 and
KCNQ3 channels (Fig. 8a–c, middle and lower). Thus, hetero-
merization likely did not confer the ability to adopt a unique pore
conformation not accessible to homomeric KCNQ2 or KCNQ3.
We therefore next tested whether homomeric KCNQ channels
were as comprehensively activated by MTX+ IVA+ RTG as was
KCNQ2/3. KCNQ3* was the most sensitive of the homomers,
and the slowest deactivating at −120 mV of all the homomers in
response to MTX+ IVA+ RTG. Interestingly, even homomeric
KCNQ4 and KCNQ5 were activated by the highest triple-drug
dose (Fig. 9a–d; Supplementary Tables 36–39). Finally, we
compared the capacity of MTX+ IVA+ RTG to hold open the
most sensitive homomer (KCNQ3*) versus heteromeric KCNQ2/
3, at −120 mV (Fig. 9e). While KCNQ2/3 deactivation was
minimal across 25 s, KCNQ3* current decayed >80% within 10 s
(Fig. 9f).
Thus, the MTX+ IVA+ RTG combination leverages the
heteromeric composition of KCNQ2/3 channels to exert optimal
synergistic effects on channel opening. Data from Figs. 7–9
suggest that a similar pore conformation is achieved for both
homomers and heteromers in the presence of MTX+ IVA+
RTG, but that in KCNQ2/3 this conformation is stable at more
negative voltages than it is for homomeric channels.
Discussion
We have discovered that IVA and MTX, two components of the
traditional African anticonvulsant M. oppositifolius leaf extract,
synergistically activate KCNQ2/3 and protect against tonic sei-
zures and associated mortality. MTX, the principal component of
Fig. 5 IVA activates neuronal KCNQs with preference for KCNQ2. a Left, Valeriana ofﬁcinalis. Right, structure (upper) and electrostatic surface potential (red,
negative; blue, positive) (lower) of isovaleric acid (IVA). b Binding position of IVA in KCNQ3 predicted by SwissDock using a chimeric
KCNQ1–KCNQ3 structure model. c Mean tail current versus prepulse voltage relationships recorded by TEVC in Xenopus laevis oocytes expressing
homomeric KCNQ1–5 channels in the absence (black) and presence (blue) of IVA (n= 4–7). Voltage protocol as in Fig. 1d. d IVA dose response at −60
mV for KCNQ2–5, quantiﬁed from data as in c (n= 4–7). e Mean tail current versus prepulse voltage relationships for wild-type KCNQ2/3 (left) or
KCNQ2-W236L/KCNQ3-W265L (right) channels in the absence or presence of IVA as indicated (n= 4–6). Voltage protocol as in Fig. 1d. f Dose response
for current increase at −60mV in response to IVA for channels as in e. g Dose response for the V0.5 of activation shift induced by IVA versus MTX in wild-
type KCNQ2/3 versus KCNQ2-W236L/KCNQ3-W265L (WL/WL) channels. IVA data (n= 4–6) quantiﬁed from e; MTX data from Fig. 3d. h Averaged
traces for KCNQ1 in the absence or presence of IVA (500 µM); n= 6. i Mean data from traces as in h. j Exemplar traces showing effects of IVA (500 µM)
with GABOB (100 µM) on KCNQ2/3 channels. Voltage protocol as in Fig. 1d. k Effects of IVA (500 µM) with GABOB (100 µM) on mean tail current (left)
and G/Gmax (right) relationships for KCNQ2/3 (n= 5) calculated from traces as in panel j. l Current fold-change at −60mV exerted by IVA (500 µM)
alone (from panel f) or with 100 µM GABOB, from data as in panel k (n= 5). m Right, dose responses for the shift in V0.5 of KCNQ2/3 activation induced
by the leaf extract compounds shown on left, calculated from traces as shown in Figs 1, 2 and 5 (n= 4–16). All error bars indicate SEM
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phenolic extracts of Mallotus, has other reported biological
activities;30,37–39 none of them readily explain anticonvulsant
efﬁcacy, but may contribute to efﬁcacy in other therapeutic uses
of M. oppositifolius, which include treatment of pain, infection,
and inﬂammation40. Historical medicinal usage of Mallotus
plants spans West Africa (M. oppositifolius) and also parts of
Asia, including Bangladesh, China, and India (M. repandus, M.
philippinensis, and others)6,41. Oral bioavailability of MTX in rats
fed Mallotus philippensis extract was previously quantiﬁed at
>20%, and plasma concentrations exceeded 2 µg/ml, reﬂecting
also the high concentration of MTX in Mallotus; e.g., the MTX
content of powder prepared from Mallotus philippensis fruit was
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Fig. 6 MTX and IVA synergize to activate KCNQ2/3 and protect against seizures. a Averaged traces showing effects of IVA and MTX on KCNQ2/3
(n= 5). Voltage protocol as in Fig. 1d. b Effects at −60mV highlighted, from traces as in a. c Mean tail current and G/Gmax from traces as in a (n= 5).
d Mean effect of IVA (500 µM)+MTX (30 µM) on KCNQ2/3 activation at +40mV and deactivation at −80mV (n= 5). ***p= 0.0009; **p= 0.001.
e Mean KCNQ2/3 current fold-increase versus voltage induced by IVA and MTX alone (from Figs. 2 and 4) or in combination (from traces as in a); n=
4–9. f Averaged traces showing effects of leaf extract cocktail (compounds shown in g) on KCNQ2/3 (n= 7). Voltage protocol as in Fig. 1d. g Effects at
−60mV highlighted, from traces as in f. h Mean tail current and G/Gmax from traces as in f (n= 7). i Mean effect of leaf extract cocktail on rates of
KCNQ2/3 activation (left) and deactivation (center; voltage protocol on right) (n= 7). *p < 0.05; **p < 0.01. j Binding position of IVA and MTX in KCNQ3
predicted by SwissDock using a chimeric KCNQ1–KCNQ3 structure model. k–m Effects of vehicle (n= 35) compared to IVA and MTX alone or in
combination (n= 11–12) on k clonic seizure incidence, l tonic seizure incidence, and m seizure assay survival in a mouse PTZ chemoconvulsant assay. *p <
0.05; **p < 0.01; ***p < 0.001. Survival statistical analysis by chi-squared, all others by one-way ANOVA. All error bars indicate SEM. All box and whisker
plots: box range, 25–75%, coefﬁcient 1; whisker range, 5–95%, coefﬁcient 1.5
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quantiﬁed as 21.25% w/w42. A plasma concentration of 2 µg/ml is
equivalent to 4 µM MTX, a concentration at which we observe
KCNQ2/3 activation even by MTX alone.
IVA has been quantiﬁed to be ~12% of the methanol extract of
the Mallotus leaf extract26. IVA is also a component of valerian
root, an herbal medicine used since ancient Greek and Roman
times to treat insomnia, and since medieval times in Europe
speciﬁcally to treat seizures34,35. Valerian root extract is still used
extensively today for anxiety and insomnia, although randomized
controlled trials evaluating its efﬁcacy have achieved mixed
results43–45. It has been estimated that 10 g of valerian root might
yield as much as 100 mg of IVA, and that valerian root doses of
30–50 g per day would have the potential for anticonvulsant
activity46. Pharmacokinetic studies in humans have been per-
formed for NPS 1776, or isovaleramide, the amide derivative of
IVA. Isovaleramide readily passes though biological membranes,
and is well tolerated in humans up to at least 2400 mg per day.
Absorption is rapid (mean Tmax of 30–45 min) and mean elim-
ination half-life is 2.5 h47. Furthermore, volatile fatty acids similar
to IVA, e.g., acetate, readily cross the blood brain barrier48. Taken
together, these studies together with our current ﬁndings suggest
that herbal extracts contain sufﬁcient bioavailable IVA to exert
effects on KCNQ2/3 channels, particularly if synergizing with
MTX.
Mutagenesis results indicating differential requirement of
W236/W265 (Fig. 5g) suggest that MTX and IVA can sit together
in the same binding pocket (Fig. 6j), a site we recently discovered
evolved to accommodate neurotransmitters including GABA28.
When combined with the modern anticonvulsant RTG, the her-
bal extracts IVA and MTX have the unprecedented capacity to
lock open KCNQ2/3 at all voltages tested, converting it into a
voltage-independent leak channel. Our cellular electrophysiology
KCNQ4
3
µA
1 s
–120 –80 –40 0 40
0
1
2
3
4
Prepulse voltage (mV)
–120 –80 –40 0
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Prepulse voltage (mV)
–120 –80 –40 0 40
–120 –80 –40 0 40 –120 –80 –40 0 40 –120 –80 –40 0 40
0
10
20
30
KCNQ3*
KCNQ3*
KCNQ3*
KCNQ2
KCNQ2/KCNQ3
KCNQ2/KCNQ3
–80 –60 –40 –20 0 20 40
0.0
0.4
0.8
1.2
Ta
il 
cu
rre
nt
 (µ
A)
Ta
il 
cu
rre
nt
 (µ
A)
Ta
il 
cu
rre
nt
 (µ
A)
Ta
il 
cu
rre
nt
 (µ
A)
Prepulse voltage (mV)
–80 –60 –40 –20 0
0.0
0.2
0.4
0.6
0.8
1.0
G
/G
m
ax
Prepulse voltage (mV)
–80 –60 –40 –20 0 20 40
0
4
8
12
Cu
rre
nt
 fo
ld
-c
ha
ng
e
Cu
rre
nt
 fo
ld
-c
ha
ng
e
Cu
rre
nt
 fo
ld
-c
ha
ng
e
Cu
rre
nt
 fo
ld
-c
ha
ng
e
+ 1 µM RTG
0.
5 
µA
1 s
Control
1
µA
1 s
–120 –80 –40 0 40
0.0
0.5
1.0
1.5
Prepulse voltage (mV)
–120 –80 –40 0
0.0
0.2
0.4
0.6
0.8
1.0
Prepulse voltage (mV)
–120 –80 –40 0 40
0
5
10
5
µA
1 s
0
2
4
6
Prepulse voltage (mV)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Prepulse voltage (mV)
0
10
20
a
RTG
TG
RTG RTG
IVA IVA
MTX
W265
MTX
RTGBinding
sites:
MTX IVA
W236 W265
W236W
26
5
KCNQ2
KCNQ2
KC
NQ
3
KCNQ3
Drugs:
1 µM RTG
1 µM MTX
1 µM IVA
1 µM RTG
10 µM MTX
10 µM IVA
10 µM RTG
30 µM MTX
500 µM IVA
KCNQ5
Cu
rre
nt
 (µ
A)
Cu
rre
nt
 (µ
A)
G
/G
m
ax
G
/G
m
ax
G
/G
m
ax
Prepulse voltage (mV)
Prepulse voltage (mV)
Prepulse voltage (mV)
Prepulse voltage (mV)
b c d
g h i
e
5 
µA
5 s
+ 10 µM RTG + 30 µM MTX + 500 µM IVA
Peak
25 s
p > 0.05
3 
µA
5 s
–80
–12025 s
Peak
25 s
f
–14
–12
–10
–8
–6
–4
–2
0
**–4
–3
–2
–1
0
Fig. 9 Leveraging heteromeric channel composition to lock open KCNQ2/3. a Averaged traces showing effects of RTG, IVA, and MTX alone or in
combination, doses as indicated, on homomeric KCNQ2–5 channels (n= 4–11). Voltage protocol as in Fig. 1d. b–d Analysis of traces as in a: b tail current;
c G/Gmax; d current fold-change versus voltage; compounds and combinations color-coded as in a. n= 4–11. e, f Effects of high-dose RTG+MTX+ IVA on
KCNQ2/3 versus KCNQ3* held at −120mV for 25 s. e Representative traces; f mean peak (0.5 s) versus steady-state (25 s) current. **p < 0.01; n= 4. Box
and whisker plots: box range, SEM, coefﬁcient of 1; whisker range 5–95%, coefﬁcient of 1.5. g Model summarizing ﬁndings. Squares represent subunits
within tetrameric KCNQ2/3 channels (yellow, KCNQ2; pale blue, KCNQ3). h Possible distinct binding positions of RTG, IVA, and MTX in one binding site in
KCNQ3 (left) versus a lower-positioned RTG binding site (center) that would overlap with binding sites for IVA and RTG (right), predicted by SwissDock
using a chimeric KCNQ1–KCNQ3 structure model. Red, KCNQ3-W265; magenta, IVA; blue, MTX; yellow, RTG. Space-ﬁlling omitted from molecules in right
panel for clarity. i Further possible poses RTG (yellow, no spaceﬁll) that would overlap with IVA (magenta) and MTX (blue) in KCNQ3 chimera model as
predicted by SwissDock. All error bars indicate SEM. All comparisons by one-way ANOVA
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06339-2 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3845 | DOI: 10.1038/s41467-018-06339-2 | www.nature.com/naturecommunications 11
and docking predictions support a mechanism for this: while
RTG is a more potent agonist of KCNQ3 (refs. 17,23), IVA and
MTX are more potent agonists of KCNQ2 (Figs. 2 and 5). Thus,
the combination of either herbal component with RTG can
leverage subunit heterogeneity in KCNQ2/3, a feature lacking in
modern anticonvulsants, to increase synergy.
The data suggest a model in which MTX and IVA are able to
bind to KCNQ2/3 across a wide range of membrane potentials
and induce a stable open conformation. One likely conﬁguration,
and potentially the dominant conﬁguration given the aforemen-
tioned subunit-speciﬁc potencies, is that in KCNQ2/3 heteromers
MTX and IVA bind to KCNQ2, and RTG to KCNQ3 (Fig. 9g),
but all combinations are considered possible. In docking studies,
RTG adopted two main sets of poses near W265—one high
(Fig. 9h, left) and one low (Fig. 9h, center). The former could
theoretically accommodate all three molecules in one binding site,
whereas the latter could not as RTG adopts essentially the same
space as IVA+ RTG in this pose (Fig. 9h, right). Indeed, RTG
more often adopted poses in which it overlapped with separately
docked IVA and MTX (more examples shown in Fig. 9i), sup-
porting the premise that in KCNQ2/3 channels, bound IVA+
MTX might prevent RTG binding to KCNQ2, but the converse
might occur in KCNQ3 (Fig. 9g).
The molecular strategy we present, utilizing a combination of
small molecules from ancient and modern therapeutics, may
provide a route to safer, more effective anticonvulsants. Through
dual synergies it lowers the effective doses required to achieve
similar KCNQ2/3 opening, increases the maximal effects, and
also considerably broadens the voltage range across which the
drugs are effective (Figs. 7 and 9e, f).
Methods
Channel subunit cRNA preparation and oocyte injection. cRNA transcripts
encoding human KCNA1, KCNQ1, KCNQ2, KCNQ3, KCNQ4, or KCNQ5 were
generated by in vitro transcription using the T7 polymerase message machine kit
(Thermo Fisher Scientiﬁc), after vector linearization, from cDNA sub-cloned into
plasmids incorporating X. laevis β-globin 5′ and 3′ UTRs ﬂanking the coding
region to enhance translation and cRNA stability. cRNA was quantiﬁed by spec-
trophotometry. Mutant cDNAs were generated by site-directed mutagenesis using
a QuikChange kit according to manufacturer’s protocol (Stratagene, San Diego,
CA) and corresponding cRNAs prepared as above. Defolliculated stage V and VI X.
laevis oocytes (Ecocyte Bioscience, Austin, TX) were injected with Kv channel α
subunit cRNAs (10 ng total per oocyte). Oocytes were incubated at 16 °C in Barth’s
saline solution (Ecocyte) containing penicillin and streptomycin, with daily
washing, for 3–5 days prior to two-electrode voltage-clamp (TEVC) recording.
Two-electrode voltage-clamp. TEVC recording was performed at room tem-
perature with an OC-725C ampliﬁer (Warner Instruments, Hamden, CT) and
pClamp10.2 software (Molecular Devices, Sunnyvale, CA) 3–5 days after cRNA
injection as described in the section above. Oocytes were placed in a small-volume
oocyte bath (Warner) and viewed with a dissection microscope. Chemicals were
sourced from Sigma. Bath solution was (in mM): 96 NaCl, 4 KCl, 1 MgCl2, 1 CaCl2,
10 HEPES (pH 7.6). Isovaleric acid, 2-mercaptophenol, 1-Heptene, and 3-ethyl-2-
hydroxy-2-cyclopenten-1-one were stored at 4 °C as 5 mM stocks in Ringer’s
solution. MTX (DMSO), sorbic acid (ethanol), and glutaconic acid (molecular
grade H2O) were stored at −20 °C as 1M stocks. Oleamide was stored as a 1 mM
stock in ethanol at 4 °C. Palmitic acid was conjugated with bovine serum albumin
as a 1 mM stock and stored at −20 °C. All compounds were diluted to working
concentrations each experimental day. All compounds were introduced to the
recording bath via gravity perfusion at a constant ﬂow of 1 ml/min for 3 min prior
to recording. Pipettes were of 1–2MΩ resistance when ﬁlled with 3M KCl. Cur-
rents were recorded in response to pulses between −80 and +40 mV at 20 mV
intervals, or a single pulse to +40 mV, from a holding potential of −80 mV, to yield
current–voltage relationships, current magnitude, and for quantifying activation
rate. TEVC data analysis was performed with Clampﬁt10.2 (Molecular Devices)
and Graphpad Prism software (GraphPad, San Diego, CA, USA); values are stated
as mean ± SEM. Normalized tail currents were plotted versus prepulse voltage and
ﬁtted with a single Boltzmann function:
g ¼ A1  A2ð Þ
1þ exp V1
2
 V
  
y þ A2
; ð1Þ
where g is the normalized tail conductance, A1 is the initial value at −∞, A2 is the
ﬁnal value at +∞, V1/2 is the half-maximal voltage of activation, and Vs the slope
factor. Activation and deactivation kinetics were ﬁtted with single-exponential
functions.
For relative permeability studies, currents were recorded in response to a single
pulse to +40 mV for 5 s, followed by pulses between −80 mV and +40 mV at 20
mV intervals, from a holding potential of −80 mV, to yield a current–voltage
relationship. According to the Goldman–Hodgkin–Katz (GHK) voltage equation:
Erev ¼
RT=F ln PK K
þ½ OþPNa Na½ OþPCl Cl½ i
 
PK K
þ½ iþPNa Na½ iþPCl Cl½ o
  ; ð2Þ
where Erev is the absolute reversal potential and P is the permeability. This permits
calculation of the relative permeability of each ion if concentrations on either side
of the membrane are known. A modiﬁed version of this equation was used here to
determine relative permeability of two ions in a system in which only the
extracellular ion concentration was known. Thus, relative permeability of Rb+,
Cs+, and Na+ compared to K+ ions was calculated for all channels by plotting the
I/V relationships for each channel with each extracellular ion (100 mM) and
comparing them to that with 100 mM extracellular K+ ion to yield a change in
reversal potential (ΔErev) for each ion compared to that of K+. Permeability ratios
for each ion compared to K+ were then calculated as
ΔErev ¼ Erev;X  Erev;K ¼
RT
zF
ln
PX
PK
ð3Þ
Values were compared between channel types and statistical signiﬁcance
assessed using ANOVA.
For calculating Rb+/K+ permeability (Fig. 3g), tail currents were elicited by a
single pulse to +40 mV, followed by a pulse at −80 mV, from a holding potential of
−80 mV in 98 mM [K+] and then 98 mM [Rb+]. The K+ or Rb+ conductance was
calculated by dividing the peak amplitude of K+ or Rb+ carried tail currents by the
driving force (difference between –80 mV, at which the tail currents are measured,
and the equilibrium potential for K+ or Rb+ ions measured in the same oocyte).
Deactivating currents were ﬁtted to a single-exponential standard function
deﬁned as follows:
Z
tð Þ ¼
Xn
i¼1
Aie
t=τi þ C: ð4Þ
Chemical structures, in silico docking, and sequence analyses. Chemical
structures and electrostatic surface potentials (range, −0.1 to 0.1) were plotted
using Jmol, an open-source Java viewer for chemical structures in 3D: http://jmol.
org/. For docking, the X. laevis KCNQ1 cryo-EM structure49 was ﬁrst altered to
incorporate KCNQ3/KCNQ5 residues known to be important for RTG and ML-
213 binding, and their immediate neighbors, followed by energy minimization
using the GROMOS 43B1 force ﬁeld50, in DeepView51. Thus, X. laevis KCNQ1
amino acid sequence LITTLYIGF was converted to LITAWYIGF, the underlined
W being W265 in human KCNQ3/KCNQ5 and the italicized residues being the
immediate neighbors in KCNQ3/KCNQ5. In addition, X. laevis KCNQ1 sequence
WWGVVTVTTIGYGD was converted to WWGLITLATIGYGD, the underlined L
being Leu314 in human KCNQ3/KCNQ5 and the italicized residues being the
immediate neighbors in KCNQ5 and/or KCNQ3. Surrounding non-mutated
sequences are shown to illustrate the otherwise high sequence identity in these
stretches. Unguided docking of mallotoxin and other compounds to predict
binding sites was performed using SwissDock52 with CHARMM forceﬁelds53.
PTZ chemoconvulsant assay. We compared anticonvulsant activities of test
compounds in male C57BL/6 mice (Charles River) aged 2–3 months. Mice were
housed and used according to the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health (NIH Publication,
8th edition, 2011). The study protocol was approved by the Institutional Animal
Care and Use Committee of University of California, Irvine, which conﬁrmed that
all relevant ethical regulations were adhered to. Chemicals were sourced from
Sigma (St. Louis, MO, USA) . A pentylene tetrazole (PTZ) chemoconvulsant assay
was used54. Mice were injected intraperitoneally with IVA and/or MTX, con-
centrations as indicated, or vehicle control (PBS with 1% DMSO), and then 30 min
later injected intraperitoneally with 80 mg kg−1 PTZ. Following the PTZ injection,
mice were caged individually and an observer (GWA) blinded to the drug used
recorded, over 20 min, clonic and tonic seizure incidence, and seizure-related
mortality.
Statistical analysis. All values are expressed as mean ± SEM. Chi-squared analysis
was used to compare seizure-related mortality in mice. One-way ANOVA was
applied for all other tests; if multiple comparisons were performed, a post-hoc
Tukey’s HSD test was performed following ANOVA. All p-values were two-sided.
Statistical signiﬁcance was deﬁned as p < 0.05.
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Data availability
The raw datasets generated during the current study are available from the corre-
sponding author on reasonable request.
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